Time to surgery does not affect oncologic outcomes in locally advanced gastric cancer after neoadjuvant chemotherapy: a meta-analysis

Future Oncol. 2023 Feb;19(5):397-408. doi: 10.2217/fon-2022-1061. Epub 2023 Mar 15.

Abstract

Aim: The authors conducted a meta-analysis to determine the association between time-to-surgery (TTS) after neoadjuvant chemotherapy and patient outcomes in locally advanced gastric cancer. Methods: Electronic databases were searched to identify potential studies, in which the authors compared patient outcomes between those with TTS within 4 (and 6) weeks of completion of neoadjuvant chemotherapy and those after 4 (and 6) weeks. Results: Six studies, including 1238 patients, were eligible for inclusion. Pooled data showed no significant differences in rates of pathological complete response, major pathological response, ypN0, complications, R0 resection and operative time between groups of longer TTS and shorter TTS. Conclusion: There was no statistically advantageous impact of prolonged TTS on pathological and surgical outcomes. Large, population-based studies are warranted.

Keywords: gastric cancer; neoadjuvant chemotherapy; pathological complete response; safety; time-to-surgery.

Publication types

  • Meta-Analysis

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Chemotherapy, Adjuvant / adverse effects
  • Humans
  • Neoadjuvant Therapy*
  • Stomach Neoplasms* / drug therapy
  • Stomach Neoplasms* / surgery